Advertisement PDL BioPharma names new vice president and CFO - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

PDL BioPharma names new vice president and CFO

PDL BioPharma, a developer of humanized monoclonal antibodies, has appointed Christine Larson as its new vice president and CFO.

Previously, Ms Larson served as a senior manager and director at Grant Thornton in their mergers and acquisitions advisory group. Prior to that time, Ms Larson was CFO for TWL Corporation, a publicly held, technology-enabled learning company.

Ms Larson has received a BS in food and nutritional sciences from the University of California, Berkeley, and an MBA from the California State University, East Bay.

John McLaughlin, president and CEO of PDL, said: “Cris began working for PDL in early October on a consulting basis, and we are pleased that she has accepted this key position following today’s completion of the spin-off of our biotechnology assets. Her background in corporate finance and investment banking brings a breadth of experience that furthers our ability to manage our royalty assets and maximize PDL’s return to its stockholders.”